Hutchison China Meditech Limited Director's Share Dealing (0984I)
19 March 2018 - 6:10PM
UK Regulatory
TIDMHCM
RNS Number : 0984I
Hutchison China Meditech Limited
19 March 2018
Director's Share Dealing
London: Monday, March 19, 2018: Hutchison China MediTech Limited
("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Dr Dan
Eldar, Non-executive Director, purchased a total of 2,768 American
Depositary Shares of the Company ("ADSs", each representing one
half of one ordinary share of US$1.00 each in the capital of
Chi-Med) on March 14, 2018 at an average price of US$36.11 per
ADS.
Following the above purchase, Dr Eldar is interested in 8,993
ADSs and 1,900 Ordinary Shares, representing approximately 0.0096%
of the current issued share capital of Chi-Med.
The notification set out below is provided in accordance with
the requirements of the EU Market Abuse Regulation.
1 Details of the person discharging managerial responsibilities/person closely associated
----- ---------------------------------------------------------------------------------------------------------------
a) Name Dr Dan Eldar
----- ------------------------------------------------------- ------------------------------------------------------
2 Reason for the notification
----- ---------------------------------------------------------------------------------------------------------------
a) Position/status Non-executive Director
----- ------------------------------------------------------- ------------------------------------------------------
b) Initial notification/Amendment Initial notification
----- ------------------------------------------------------- ------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----- ---------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
----- ------------------------------------------------------- ------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
----- ------------------------------------------------------- ------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----- ---------------------------------------------------------------------------------------------------------------
a) Description of the financial instrument, type of ADS each representing one half of one Ordinary Share
instrument of US$1.00
Identification code ADS ISIN: US44842L1035
----- ------------------------------------------------------- ------------------------------------------------------
b) Nature of the transaction Acquisition of 2,768 ADSs on March 14, 2018 at an
average price of US$36.11 per ADS
----- ------------------------------------------------------- ------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
---------- ----------
US$36.12 2,700
---------- ----------
US$35.74 68
---------- ----------
----- ------------------------------------------------------- ------------------------------------------------------
d) Aggregated information
- Aggregated volume N/A
- Price
----- ------------------------------------------------------- ------------------------------------------------------
e) Date of the transaction 2018-03-14
----- ------------------------------------------------------- ------------------------------------------------------
f) Place of the transaction
Nasdaq Stock Market
----- ------------------------------------------------------- ------------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate
Finance & Development +852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedewerogerson.com
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLIFERVRIALIT
(END) Dow Jones Newswires
March 19, 2018 03:10 ET (07:10 GMT)
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From May 2023 to May 2024
